Ally Bridge Group’s Relmada Therapeutics RLMD Stock Holding History

Ally Bridge Group’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-210,525	Closed	-$1.47M	–	35
2026 Q1	$1.47M	Buy	+210,525	New	+$996K	1.18%	26
2022 Q3	–	Sell	-160,000	Closed	-$3.04M	–	44
2022 Q2	$3.04M	Buy	+160,000	New	+$3.49M	2.77%	17

Other funds holding RLMD

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ally Bridge Group's RLMD Position: Q2 2026 in Review

Ally Bridge Group sold out of Relmada Therapeutics (RLMD) in Q2 2026, closing a stake of 210,525 shares — an estimated $1.47M sold.

Ally Bridge Group first reported a position in RLMD in Q2 2022 and held it in 2 quarters. The position peaked at $3.04M in Q2 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

Ally Bridge Group reported no remaining Relmada Therapeutics position as of Q2 2026 after selling out during the quarter.
Ally Bridge Group sold 210,525 Relmada Therapeutics shares in Q2 2026, an estimated $1.47M.
Ally Bridge Group first reported a position in Relmada Therapeutics in Q2 2022 and held it in 2 quarters.
Ally Bridge Group's Relmada Therapeutics position peaked at $3.04M in Q2 2022.
126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Ally Bridge Group's 13F filing for Q2 2026, filed 14 Aug 2026.